Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760378 | 0.91 | CHRM2 (0.73) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL6760374 | 0.91 | CHRM2 (0.73) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL13931011 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL722238 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL23658364 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL23658362 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL413300 | 0.89 | CHRM2 (0.64) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL156133 | 0.86 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL12875999 | 0.86 | CHRM2 (0.56) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL14314599 | 0.85 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4536637-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025068132-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025017045-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| WO-2023240084-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240084-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-109923116-B | [1,2,4] triazolo [1,5-a ] pyrimidine derivatives as PDE2 inhibitors | 詹森药业有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2021-03-16 | — | — | US | disclosed |
| EP-3535267-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-30 | — | — | EP | disclosed |
| US-20190276462-A1 | [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
| EP-3535267-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-09-11 | — | — | EP | disclosed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276462-A1 | [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | CHRM2 929/4885CHRM1 1156/4885CHRM3 1371/4885 |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CHRM2 7/4885CHRM1 11/4885CHRM3 44/4885 |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | CHRM2 4765/4885CHRM1 4281/4885CHRM3 4483/4885 |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GLP1R | CHRM2 1791/4885CHRM1 1616/4885CHRM3 763/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CHRM2 7/4885CHRM1 11/4885CHRM3 44/4885 |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | CHRM2 1057/4885CHRM1 1271/4885CHRM3 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.